Interview with Christian Schilling, CEO, Boehringer Ingelheim Austria
Austria has always been a strategic market for the group: it has played a key role in Boehringer Ingelheim’s success story, as this is where the company established its first…
Address: ‘Dr.-Boehringer-Gasse 5-11
A-1121 Wien’
,Austria
Tel: (+43 1) 80 105-0
Web: http://www.boehringer-ingelheim.at/
Boehringer Ingelheim – one of the world‘s 20 leading pharmaceutical companies
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.
As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim’s endeavors.
For more information please visit www.boehringer-ingelheim.com
Boehringer Ingelheim in Austria
Boehringer Ingelheim founded its first subsidiary outside Germany in a Viennese pharmacy in 1948. From these modest beginnings, the Austrian company has developed into a modern high technology concern.
Today the company is of great importance as a cancer research centre and one of the three biopharmaceutical research, development and production centres in the international group. As the Regional Center Vienna it is responsible for the pharmaceutical business (human pharmaceuticals and animal health) and for clinical trials in more than 30 countries in Central and Eastern Europe (including Austria).
Over the last years Boehringer Ingelheim has created 530 new jobs in Vienna and invested around 360 million euros in the Vienna site.
Activities of the Boehringer Ingelheim Regional Center Vienna
• Business responsiblity for Boehringer Ingelheim products in more than 30 countries of Central and Eastern Europa – Human Pharmaceuticals and Animal Health
• International Oncology Research Center
• Clinical Research in all therapeutic areas of the Corporation in Central and Eastern Europe (including Austria and Switzerland), Turkey, South Africa and Israel
• Biopharmaceutical research, development and production
Boehringer Ingelheim Regional Center Vienna
The Regional Center Vienna (RCV) is responsible for the human pharmaceuticals (prescription medicines and over-the-counter products) and animal health business in more than 30 Central and Eastern European countries. Moreover the whole clinical research of the region is managed by the RCV. Vienna is the oncology research center and a center of biopharmaceutical research, development and production in the international group of companies. Boehringer Ingelheim is also engaged in basic research, represented by the Research Institute of Molecular Pathology (IMP) in Vienna. Therefore BI is one of the most research focused pharmaceutical companies in Austria. In 2011 the Boehringer Ingelheim Regional Center Vienna earned 736,2 million euros and had about 3,000 employees in Austria and Eastern Europe.
Animal Health
International Research Center of Oncology
Clinical research in all therapeutic areas of the business association – studies in 15 countries of Central and Eastern Europe (including Austria)
Biopharmaceutical development and manufacturing of pharmaceuticals
Austria has always been a strategic market for the group: it has played a key role in Boehringer Ingelheim’s success story, as this is where the company established its first…
Ard van der Meij, country president of Novartis Group Austria, the nation’s leading pharmaceutical company, discusses the advantages in Austria for innovative companies and the steps required to bolster the…
Prof. Dr. Robin Rumler, country manager of Pfizer Austria, discusses the evolution of their operations, especially since taking over the TBE and meningitis vaccine production plant, as well as the…
Austria has long been merely a cog in the wheel of global R&D, lying in the shadows of neighboring research giants, Germany and Switzerland. Now, however, this perception is changing…
Dr. Sabine Mӧritz-Kaisergruber and Helmut Kaisergruber, CEOs of Astro Pharma, a young vibrant Austrian pharmaceutical company, discuss their tailored strategy to establish themselves within the Austrian market as well as…
Clemens Schödl, general manager of Gilead Austria, discusses Gilead’s footprint and reputation in Austria as the leading global player in HIV treatment and what must be done to bring Austrian…
Siegfried Leitner, general manager of Accord Austria and Germany, and CEO and co-founder of A-med, provides an insight into the early years of his Accord affiliate and how it was…
Robert Sauermann, head of the department of pharmaceutical affairs in the Main Association of Austrian Social Security Institutions, which publishes the national code of reimbursement, provides an in-depth look into…
Dr. Jan Oliver Huber, secretary general of the Association of the Pharmaceutical Industry in Austria, or PHARMIG, which represents 120 member companies and 95 percent of the medicinal product market…
Martin Peithner, CEO of Dr. Peithner and Austroplant, two leading medical companies focusing on homeopathic and herbal medicines in Austria, discusses the evolution of the companies over the last five…
Arnoldas Doviltis, general manager of Ferring Austria, a research-driven Swiss biopharmaceutical company, elaborates on the autonomous nature of local Ferring affiliates and how this allows a tailored approach to conduct…
Eva Bano, CEO of BANO, an exciting west Austrian company, discusses the company’s modern revamp and expansion from natural therapies to pharmaceutical products. She also explains the importance of a…
Erich Lehner, head of the life science branch at EY Austria, a worldwide leading consultancy firm, provides an insight into the current mandate of EY Austria as well as the…
See our Cookie Privacy Policy Here